Abstract |
In an open clinical trial 19 patients with angina pectoris (functional class II-III) received in turn either non-retard tablets of isosorbide dinitrate (nitrosorbid, cardiket) in a mean dose 80 mg/day or isosorbide 5-mononitrate (mono mac) in a mean dose 51.5 mg/day. Each drug was given for a month. The effect was assessed by changes in frequency of anginal attacks and exercise tolerance. Non-retard isosorbide dinitrate and isosorbide 5-mononitrate demonstrate a good antiischemic effect, are safe and well tolerated. Isosorbide dinitrate and mononitrates do not differ significantly in reduction of the anginal attacks and by an increase in exercise tolerance but the effective dose of mono mac was 1.5-2 times less than that of nitrosorbide or cardiket, thus it is more cost-effective.
|
Authors | V P Lupanov, I A Alekseeva, N N Vasil'eva, Kh Kh Chotchaev, V G Naumov |
Journal | Klinicheskaia meditsina
(Klin Med (Mosk))
Vol. 78
Issue 9
Pg. 52-5
( 2000)
ISSN: 0023-2149 [Print] Russia (Federation) |
Vernacular Title | Sravnitel'noe izuchenie izosorbida di- i mononitratov u bol'nykh ishemicheskoĭ bolezn'iu serdtsa so stabil'noĭ stenokardieĭ, obuslovlennoĭ stenoziruiushim koronarnym aterosklerozom. |
PMID | 11051743
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Vasodilator Agents
- Isosorbide Dinitrate
- isosorbide-5-mononitrate
|
Topics |
- Aged
- Angina Pectoris
(complications, drug therapy, economics)
- Coronary Artery Disease
(complications, drug therapy, economics)
- Coronary Disease
(complications, drug therapy, economics)
- Cost-Benefit Analysis
- Female
- Humans
- Isosorbide Dinitrate
(analogs & derivatives, economics, therapeutic use)
- Male
- Middle Aged
- Myocardial Ischemia
(complications, drug therapy, economics)
- Vasodilator Agents
(economics, therapeutic use)
|